12 Best CRISPR Therapeutics Alternatives & Competitors (2026)

Recursion Pharmaceuticals runs one of the largest automated wet-lab-plus-AI platforms, generating millions of cellular images to map disease biology. Its strength lies in scale of phenotypic screening and an advancing clinical pipeline. Compared with Algen Biotechnologies, Recursion is less focused on CRISPR gene modulation and more on high-content imaging; both companies pursue big-pharma partnerships but Recursion is already public with broader disease coverage.

Recursion Pharmaceuticals runs one of the largest automated wet-lab-plus-AI platforms, generating millions of cellular images to map disease biology. Its strength lies in scale of phenotypic screening and an advancing clinical pipeline. Compared with Algen Biotechnologies, Recursion is less focused on CRISPR gene modulation and more on high-content imaging; both companies pursue big-pharma partnerships but Recursion is already public with broader disease coverage.

Kite Pharma, under Gilead, markets approved autologous CAR-T therapies with strong clinical outcomes in blood cancers. High cost and ex vivo processing differentiate it from Kernal’s in vivo, lower-cost vision backed by ARPA-H.

Ginkgo Bioworks provides high-throughput synthetic biology foundry services for engineering organisms and pathways. It offers cell-programming scale but lacks Algen’s disease-focused CRISPR modulation and AI RNA-network models. Ginkgo’s model is service-based with foundry capacity fees, suiting different use cases than therapeutic discovery.

Insilico Medicine applies generative AI and reinforcement learning primarily to small-molecule design, moving from target to IND in record time for several programs. Unlike Algen’s CRISPR-driven functional genomics, Insilico starts from omics data and chemistry engines. It offers lower upfront costs via software licensing but lacks Algen’s wet-lab gene-modulation datasets and Doudna-derived precision editing capabilities.

Moderna develops mRNA therapeutics and vaccines with broad tissue delivery but lacks Kernal’s AI-driven selective translation for precise T-cell CAR programming. Its platform excels in rapid manufacturing and approved products yet focuses less on in vivo cell engineering for cancer or autoimmunity. Pricing is commercial for vaccines; Kernal remains pre-commercial with targeted oncology focus.

Moderna develops mRNA therapeutics and vaccines with broad tissue delivery but lacks Kernal’s AI-driven selective translation for precise T-cell CAR programming. Its platform excels in rapid manufacturing and approved products yet focuses less on in vivo cell engineering for cancer or autoimmunity. Pricing is commercial for vaccines; Kernal remains pre-commercial with targeted oncology focus.

Exscientia combines patient tissue data with generative design to create precision medicines, emphasizing rapid design-make-test cycles. Its platform is chemistry-centric rather than CRISPR-centric. Relative to Algen Biotechnologies, Exscientia provides stronger early chemistry optimization but weaker direct causal gene-to-phenotype mapping at single-cell resolution.

Atomwise applies deep learning to structure-based virtual screening for small molecules. It provides rapid hit identification without wet-lab gene modulation. Relative to Algen, Atomwise is chemistry-first and lower cost for early screening but cannot replicate the causal biology resolution delivered by AlgenCRISPR and AlgenBrain.

BioNTech operates a diversified mRNA pipeline including oncology candidates using lipid nanoparticles. It shares mRNA roots with Kernal but emphasizes personalized neoantigen vaccines over in vivo CAR-T selectivity. Larger scale and approved products give it commercial reach Kernal currently lacks.

CRISPR Therapeutics develops CRISPR-based gene editing therapies primarily for blood disorders and oncology. Its platform uses existing delivery methods like lipid nanoparticles or AAVs optimized for liver and hematopoietic cells rather than kidney or pancreas. Compared to Nephrogen, it has advanced clinical programs and larger scale manufacturing but does not address the tissue-specific delivery bottleneck for renal or pancreatic diseases.